March 31, 2010
March 30, 2010
March 25, 2010
Biotech tropicana Journal Mini Business Plan published at:
March 16, 2010
a) REMINDER
From the CEO
On January 22, 2010, we published a notice alleviating payment conditions of debts due to Biotech tropicana, Inc for services to various institutions. Here, we remind that we are two (2) weeks away from the debt relief bonus deadline. We aim to notify parties that fail to react, not to write to the Biotech tropicana, Inc executive office, after the March 31, 2010 deadline. They will receive appointment letters from the business court.
We take this opportunity to thank the parties that took advantage of the Biotech tropicana, Inc debt relief program, and wish them the best toward future collaborations in the best interest of all parties.
Sincere Salutations
March 11, 2010
March 9, 2010
Biotech tropicana Corporation Mini Business Plan published at
and
March 7, 2010
March 5, 2010
March 3, 2010
SMARTcompostTECHS project lunched.
SMARTcompostTECHS is with SMARThivTECHS, the second active project at trial phase.
March 2, 2010
USA-RSA Axis Principle Established
Based on preliminary findings of the pre-clinical trials of the SMARThivTECHS initiated January 1, 2010, the founders have recommended the USA-RSA axis for further development of the Biotech tropicana SMARThivTECHS.
This decision is based on many factors including the facts that:
a) The United States of America (USA) are the biggest DONOR in the world in the fight against HIV/AIDS in te developing world
b) Africa is the biggest RECIPIENT of HIV patients in the world
c) South Africa (RSA) is the technically more advanced country in Africa; therfore more suitable for further technical development of the SMARThivTECHS
d) The Associate founder and co-owner of Biotech tropicana Corporation is a citizen of the United States of America
e) The founder and co-owner of the Biotech tropicana Corporation is a citizen of Benin (AFRICA).
f) Additional parties that do not fit in the USA-RSA axis may be considered as we go, on need basis. Here, the primary interest of the patients, the commercial interest of Biotech tropicana Corporation, and the recommendations of the authorities in the field, are and will remain, the controlling principles.
After a careful analysis of all factors essential for a succesful and particularly important "competitive" development of the SMARThivTECHS, the founders have determined that the USA-RSA axis, is the best strategy for both the commercial interest of Biotech tropicana Corporation, and the most important health interest of more than 40 millions patients, 5 times the population of a country like Benin, who are the primary target of the SMARThivTECHS, consistent with recommendations of the authority, under point 6 of the United Nations Millennium Development Project
March 1, 2010
As part of the measures announced by the founder in a short communication dated February 26, 2010 in the NewsBLOG, the founder and CEO announced the following:
a) By decision 01-03-2010_foundation, starting March 1, 2010, a security unit is created in the Biotech tropicana, Inc GROUP. The unit is named Biotech tropicana,IncSECURITY. Its mission is to ensure the protection of the properties and the staff of the Biotech tropicana system.
b) Upon establishment of full capacity and necessary collaboration, Biotech tropicana, Inc SECURITY will be merged with Biotech tropicana, IncFORENSICS unit.
c) Negotiations are initiated for contracting with private security agencies in South AFRICA and the United States of America for improving the security of the properties of the Biotech tropicana system.
d) A SMARThivTECHS tech trials security task force is established. Data on the activities of the task force, will be published in the a SECURITY BLOGS hosted in the Biotech tropicana TECH TRIALS HOME website at www.http://btitechtrials.ucoz.com/blog .
|
